Predictive
Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”)
to personalized medicine and drug discovery, is utilizing the combined
capabilities of AI with its extensive database of tumor data to assist
clinicians in selecting the most effective drug treatments for cancer patients.
An article discussing the company reads, “One disruptive aspect of POAI’s
technology is that it helps the clinician to increase the chance of choosing
more effective therapy, resulting in potential reduction of side-effects as
well as cost savings. Traditionally oncologists prescribe what drugs they think
have the best chance at beating a patient’s cancer, and the drug may or may not
prove effective. Meanwhile, the patient’s undergoes chemotherapy with often
debilitating side effects. If the drug proves to be a poor fit for the
patient’s cancer, the chemotherapy experience will have been in vain, and the
patient must continue acting as a guinea pig in experimenting with the next
likely drug candidate. This is the standard cancer treatment of today. However,
by utilizing POAI’s innovative tumor-profiling platform, which literally
performs chemotherapy on the patient’s tumor outside the body to determine
which drug is most effective, the patient can be spared many of the risks of
being a ‘guinea-pig’ as the oncologist attempts different drugs.”
To view the full article, visit http://ibn.fm/3O5lq
About Predictive Oncology Inc.
Predictive Oncology is an AI-driven company focused on
applying artificial intelligence to personalized medicine and drug discovery.
The company applies smart tumor profiling and its AI platform to extensive
genomic and biomarker patient data sets to predict clinical outcomes and, most
importantly, improve patient outcomes for cancer patients of today and
tomorrow. Predictive Oncology currently has approximately 150,000 clinically
validated cases on its molecular information platform, with more than 38,000 specific
to ovarian cancer. The company’s data is highly differentiated, having both
drug-response data and access to historical outcome data from patients.
Predictive Oncology intends to generate additional sequence data from these
tumor samples to deliver on the clear unmet market need across the
pharmaceutical industry for a multi-omic approach to new drug development. For
more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news breaks
keep you up-to-date with the day’s top movers. MissionIR is primarily focused
on strategic communications. We have executed countless communications programs
to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
